Mersana Announces Fast Track Grant from FDA for Its Targeted B7-H4
ADC评论
September 14, 2022
On September 12, Mersana announced that its ADC product XMT-1660 targeting was granted Fast Track designation by the FDA for the treatment of adult patients
